
Sign up to save your podcasts
Or


Based on Podcast App listening data
While last week’s episode covered ample ground when it came to lightning strikes, there is so much more to the world of electricity left to explore. Fortunately, there’s a bonus episode for that! This week, we’re joined by a familiar voice, Dr. Timothy Jorgensen, whose previous appearance on the podcast (see Ep 53 Radiation: X-Ray Marks the Spot) helped to lay out the basics of radiation. In this bonus episode, Dr. Jorgensen, Professor of Radiation Medicine and Director of the Health Physics Graduate Program at Georgetown University, returns to the pod to help us dig deeper into the vast topic of electricity. His latest popular science book, Spark: The Life of Electricity and the Electricity of Life, gives us much to talk about, from how electricity works to the difference between direct and alternating current, from electric fish to ECT, and beyond. As an accomplished science writer, Dr. Jorgensen also shares some insights into using storytelling as a teaching tool and advice for those who may want to become better science communicators themselves. Tune in wherever you get your podcasts!
See omnystudio.com/listener for privacy information.
See omnystudio.com/listener for privacy information.
In last week’s episode, we explored the mysterious world of multiple sclerosis (MS) and the ongoing quest to determine what causes this autoimmune disease. While it’s likely that no one single factor leads to the development of MS, the Epstein-Barr virus (EBV) has long been suspected to play a role in this and many other autoimmune diseases and has also been shown to be involved in several cancers. But why? How is this virus implicated in so many diseases? How does it infect us? What does it do once it’s in our bodies? Dr. Micah Luftig, Associate Professor and Vice Chair in the Department of Molecular Genetics and Microbiology at Duke University, helps to answer these questions and many more about this surprising virus. Not only does Dr. Luftig share his expert knowledge in all things EBV in this interview, he also sheds some light on what a career in academia is like and drops some great advice on how to feel out whether a research career might be right for you. Tune in wherever you get your podcasts!
See omnystudio.com/listener for privacy information.
See omnystudio.com/listener for privacy information.
We ended our myxoma virus episode on a bit of a cliffhanger, briefly alluding to the emergence of another deadly rabbit virus on the global scene. In this follow-up bonus episode, we take a closer look at this recent arrival, rabbit hemorrhagic disease virus (RHDV), and what its rapid spread around the world has meant for both invasive European rabbits in Australia as well as native rabbit species around the world. Dr. Robyn Hall (@Virologica), veterinary virologist, epidemiologist, and Team Leader of the Rabbit Biocontrol Team at CSIRO in Australia, walks us through how this virus earned the nickname “bunny Ebola”, where it seems to be having the most impact, and what the sudden appearance of a new type of RHDV has taught us about viral evolution and ecological cascades. Then, once we fill up on RHDV facts, we talk favorite viruses, life as a veterinary virologist, and so much more! Tune in wherever you get your podcasts. And check out our website for links to where you can learn more about this fascinating and deadly virus.
See omnystudio.com/listener for privacy information.
See omnystudio.com/listener for privacy information.
Our episode last week ended on a hopeful note, a rare occurrence for this podcast, and it was due in large part to the incredible decline in reported cases of human African trypanosomiasis (HAT) over the past decade. In this bonus episode, we explore one of the major reasons behind this drop in HAT: the new medication fexinidazole, developed through a partnership between the Drugs for Neglected Diseases initiative (DNDi), a non-profit organization dedicated to developing new treatments for neglected diseases and Sanofi, a French healthcare company. We are thrilled to be joined by two researchers from DNDi, Dr. Nathalie Strub-Wourgaft and Dr. Wilfried Mutombo Kalonji, who share their insights into the challenges associated with bringing a medication all the way from its development stage, to testing it in the field, and finally ensuring that access is provided for those who need it most. We also chat about how this treatment works, the impact that COVID-19 has had on screening efforts for sleeping sickness, the lessons learned from fexinidazole’s development, and so much more. Tune in wherever you get your podcasts! And when you’re finished with the ep, check out this beautiful video from DNDi chronicling the story of fexinidazole: A doctor’s dream: A pill for sleeping sickness.
See omnystudio.com/listener for privacy information.
See omnystudio.com/listener for privacy information.
Blood tests and liver function results can only tell us part of the story when it comes to the impact that hepatitis B has on people living with the virus. Far too often overlooked is how stigma and discrimination, which we only briefly touched upon in our last episode, contribute to the substantial global burden of disease. In this bonus episode, Dr. Chari Cohen, Senior Vice President of the Hepatitis B Foundation, comes on the pod to chat about the different forms stigma and discrimination can take, how we can get a better sense of their impact, and the key tools in the fight against them. We also seized this opportunity to pick Dr. Cohen’s brain about what it’s like to run a public health non-profit, how much of the job is accurately reflected in the job title, and advice for someone who might be interested in pursuing a career in public health.
See omnystudio.com/listener for privacy information.
This week, we’re dipping a toe back into the vast waters of hepatitis viruses, this time with a focus on hepatitis B. The hepatitis B virus, though second to be named, was first to be discovered, and effective vaccines and treatments have been available for decades. Yet the global prevalence of this virus remains staggering, with nearly 300 million people chronically infected and 1.5 million new infections annually. So what’s going on? In this episode, we weave our way through the complicated biology of this virus and its deadly potential, the strange history of its identification that shows that you don't have to be looking for something to find it, and the current status of this virus that underlines how safe, effective tools for disease prevention are only as good as our delivery infrastructure. We are also so excited to be joined by Dr. Su Wang, Medical Director for the Center for Asian Health & Viral Hepatitis Programs at the Cooperman Barnabas Medical Center and outgoing President of the World Hepatitis Alliance.
See omnystudio.com/listener for privacy information.
From the publisher's feed
Ranked by our users in the last 21 days

37,534 Listeners

14,817 Listeners

171,919 Listeners

7,665 Listeners

24,517 Listeners

21,914 Listeners

15,010 Listeners

3,353 Listeners

3,337 Listeners

25,314 Listeners

3,350 Listeners

4,840 Listeners

7,694 Listeners

2,421 Listeners

16,688 Listeners

3,812 Listeners

7,090 Listeners

7,180 Listeners

4,141 Listeners

1,053 Listeners

434 Listeners

2,226 Listeners

945 Listeners

20 Listeners